VPA-related axial skeletal defects and apoptosis: A proposed event cascade

Reproductive Toxicology

Volumn 29, Issue 1, 2010, Pages 106-112

  Di Renzo, Francesca ^a   Broccia, Maria Luisa ^a   Giavini, Erminio ^a   Menegola, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Embryo; Mechanisms; Mouse; p53; Skeletal malformations; Somites; Valproic acid

Indexed keywords

CASPASE 3; DNA; HISTONE DEACETYLASE; PROTEIN P53; SIRTUIN 1; TRICHOSTATIN A; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; EMBRYO; EMBRYOTOXICITY; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SKELETON MALFORMATION; SOMITE;

ABNORMALITIES, DRUG-INDUCED; ACETYLATION; ANIMALS; ANTICONVULSANTS; APOPTOSIS; BLOTTING, WESTERN; BONE AND BONES; CASPASE 3; DNA FRAGMENTATION; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; FEMALE; GESTATIONAL AGE; HISTONES; IMMUNOHISTOCHEMISTRY; MICE; PREGNANCY; SIRTUIN 1; SOMITES; TUMOR SUPPRESSOR PROTEIN P53; VALPROIC ACID;

MUS;

EID: 73449110127     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2009.10.004     Document Type: Article

References (36)

1. Nau H., and Hendrickx G. Valproic acid teratogenesis. ISI Atlas Sci: Pharmacol (1987) 52-56
2. Nau H. Valproic acid-induced neural tube defects. Ciba Found Symp 181 (1994) 144-152
3. Menegola E., Broccia M.L., Nau H., Prati M., Ricolfi R., and Giavini E. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen 16 (1996) 97-108
4. Faiella A., Wernig M., Consalez G.G., Hostick U., Hofmann C., Hustert E., et al. A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genet 9 (2000) 227-236
5. Nau H., Hauck R.S., and Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 69 (1991) 310-321
6. Blaheta R.A., Nau H., Michaelis M., and Cinatl Jr. J. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 9 (2002) 1417-1433
7. Eikel D., Lampen A., and Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 19 (2006) 272-278
8. Göttlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 (2001) 6969-6978
9. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
10. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276 (2001) 36734-36741
11. Gurvich N., Berman M.G., Wittner B.S., Gentleman R.C., Klein P.S., and Green J.B. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 19 (2005) 1166-1168
12. Menegola E., Di Renzo F., Broccia M.L., Prudenziati M., Minucci S., Massa V., et al. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B 74 (2005) 392-398
13. Menegola E., Di Renzo F., Broccia M.L., and Giavini E. Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Res C 78 (2006) 345-353
14. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., and Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45 (2005) 495-528
15. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
16. Marks P.A., Richon V.M., Kelly W.K., Chiao J.H., and Miller T. Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 259 (2004) 269-281
17. Liu T., Kuljaca S., Tee A., and Marshall G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32 (2006) 157-165
18. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
19. Xu W., Ngo L., Perez G., Dokmanovic M., and Marks P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103 (2006) 15540-15545
20. Kuendgen A., and Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 110 (2007) 943-954
21. Krämer O.H., Knauer S.K., Zimmermann D., Stauber R.H., and Heinzel T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27 (2008) 732-740
22. Wlodarczyk B.C., Craig J.C., Bennett G.D., Calvin J.A., and Finnell R.H. Valproic acid-induced changes in gene expression during neurulation in a mouse model. Teratology 54 (1996) 284-297
23. Ichiyama T., Okada K., Lipton J.M., Matsubara T., Hayashi T., and Furukawa S. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res 857 (2000) 246-251
24. Dawson J.E., Raymond A.M., and Winn L.M. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. Toxicol Appl Pharmacol 211 (2006) 124-132
25. Záskodová D., Rezácová M., Vávrová J., Vokurková D., and Tichy A. Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation. Ann N Y Acad Sci 1091 (2006) 385-398
26. de la Cruz-Hernández E., Pérez-Cárdenas E., Contreras-Paredes A., Cantú D., Mohar A., Lizano M., et al. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol J 26 (2007) 4-18
27. Cheng H.L., Mostoslavsky R., Saito S., Manis J.P., Gu Y., Patel P., et al. Developmental defects and p53 hyperacetylation in Sirt2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 100 (2003) 10794-10799
28. Okada A., Kushima K., Aoki Y., Bialer M., and Fujiwara M. Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. Birth Defects Res A 73 (2005) 229-238
29. Tam P.P.L. A study on the pattern of prospective somites in the presomitic mesoderm of mouse embryos. J Embriol Exp Morphol 92 (1986) 269-285
30. Nau H. Valproic acid teratogenicity in mice after various administration and Phenobarbital-pretreatment regimens: the parent drug and not one of metabolites assayed is implicated as teratogen. Fundam Appl Toxicol 6 (1986) 662-668
31. Tam P.P.L. The control of somitogenesis in mouse embryos. J Embriol Exp Morphol 65 (1981) 103-128
32. Zucker R.M., Elstein K.H., Shuey D.L., Ebron-McCoy M., and Rogers J.M. Utility of fluorescence microscopy in embryonic/fetal topographical analysis. Teratology 51 (1995) 430-434
33. Abrams J.M., White K., Fessler L.I., and Steller H. Programmed cell death during Drosophila embryogenesis. Development 117 (1993) 29-43
34. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 72 (1976) 248-254
35. Bateson W. Materials for the study of variation: treated with special regard to discontinuity in the origin of species (1894), Macmillan and Co., New York
36. Di Renzo F., Cappelletti G., Broccia M.L., Giavini E., and Menegola E. The inhibition of embryonic histone deacetylases as the possible mechanism accounting for axial skeletal malformations induced by sodium salicylate. Toxicol Sci 104 (2008) 397-404